- Unlock the 99.9% Unknown: Our proprietary AI decodes unmapped microbial DNA that traditional methods miss, discovering novel biomarkers beyond the reach of reference-based approaches
- Improve Drug Response Rates: Stratify patients to double efficacy while reducing side effects for non-responders
- Ready-to-License Assets: Validated biomarkers already developed for major biologics
- Over 100,000 novel biomarkers already discovered: demonstrated efficacy prediction in large-scale animal study as well as human Crohn’s and Colitis trial.
Sponsor(s):
Alphabiome AI
Speaker(s):
Dr. Yaniv Altshuler
CEO & Founder
Alphabiome
Time:
12:45 PM - 1:15 PM
Agenda Track No.:
Track 1
Session Type:
General Session (Presentation)